Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Drug-Resistant Superbugs, Multi-drug Resistant Organisms: MRSA, VRE, Clostridium difficile, and CRE. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Drug-Resistant Superbugs, Multi-drug Resistant Organisms: MRSA, VRE, Clostridium difficile, and CRE (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 106 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Detection, Identification, and Susceptibility Testing of CRE

Clinically relevant members of the Enterobacteriaceae are frequently isolated in the laboratory from a variety of sources. It is very important to accurately detect CRE in order to properly treat patients and prevent the spread of MDROs.
CRE detection and antimicrobial susceptibility testing
The best way to detect CRE is to ensure the use of current breakpoints in antimicrobial susceptibility testing (AST). With commercial AST systems, contact the manufacturer to verify the breakpoint status used. When using the current Clinical and Laboratory Standards Institute (CLSI) AST breakpoints, carbapenemase-producing Enterobacteriaceae (CPE) will usually test intermediate to resistant to one or more of the carbapenems. They further note that of the carbapenems, ertapenem nonsusceptibility is the most sensitive indicator of carbapenemase production.
The most recent edition of the Clinical and Laboratory Standards Institute (CLSI) document M100S (table 2A-1) provides the carbapenem zone diameter and MIC breakpoint guidelines for Enterobacteriaceae.
The most current Food and Drug Administration (FDA) breakpoints are available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsa ndTobacco/CDER/ucm275763.htm. Accessed January 26, 2017.
Detection of carbapenemase
Detecting the presence of carbapenemase in CRE is not recommended for routinely guiding patient therapy, as long as the most current AST breakpoints are being used. However, there may be facility infection control procedures or epidemiological reasons that may warrant detecting the presence of carbapenemase, including when a CRE outbreak is suspected or in an effort to gain a better understanding of emerging resistance patterns. Tests to detect the presence of carbapenemase in Enterobacteriaceae (as well as Pseudomonas aeruginosa and Acinetobacter species) include the modified Hodge test (MHT), CarbaNP test (CNPt), carbapenem inactivation method (CIM), and various molecular methods. There is not a single phenotypic carbapenemase method that will detect all carbapenemases. It is critical to consult the most recent guidelines due to the rapidly changing resistance mechanisms present in Enterobacteriaceae.